Braidwell LP Buys New Position in Zura Bio Limited (NASDAQ:ZURA)

Braidwell LP bought a new stake in Zura Bio Limited (NASDAQ:ZURA) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 2,472,806 shares of the company’s stock, valued at approximately $10,040,000. Braidwell LP owned approximately 3.68% of Zura Bio at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZURA. MetLife Investment Management LLC purchased a new position in shares of Zura Bio in the third quarter valued at approximately $111,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Zura Bio during the 3rd quarter worth approximately $46,000. The Manufacturers Life Insurance Company purchased a new position in Zura Bio in the 3rd quarter valued at approximately $71,000. Valence8 US LP acquired a new position in shares of Zura Bio in the third quarter worth $71,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Zura Bio by 51.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after acquiring an additional 98,972 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $3.00 on Friday. The stock’s 50-day simple moving average is $4.07 and its 200-day simple moving average is $4.02. Zura Bio Limited has a fifty-two week low of $2.00 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, research analysts predict that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Leerink Partners initiated coverage on Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price for the company. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Piper Sandler reissued an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Finally, HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $15.80.

Insider Buying and Selling at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This trade represents a 2.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 22.10% of the stock is currently owned by insiders.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.